Skip to content

CROI: Is tenofovir causing kidney problems?

CROI: Treatment changes and breaks occur at high rate in Ugandan HIV patients

CROI: High dietary fat and cholesterol contribute to serum lipid levels in people with HIV

CROI: High rate of virologic failure on once-daily combination of 3TC, tenofovir and nevirapine

CROI: Therapeutic concentrations of efavirenz, Kaletra, could be difficult to achieve in some children, with or without rifampicin

CROI: Sexually transmitted infections significantly increase risk of drug-resistant HIV transmission

CROI: Experimental 'salvage' integrase inhibitor, elvitegravir (GS-9137) appears potent at higher doses

CROI: SMART substudy finds people on treatment less likely to transmit HIV, and may take fewer risks

CROI: New NNRTI, TMC278, demonstrates sustained potency, better CNS and lipid profile than efavirenz, in treatment-naive